These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26216068)

  • 61. [Preventing recurrence of liver cirrhosis due to hepatitis C virus infection. A critical factor for improving the results of liver transplantation].
    García-Retortillo M
    Gastroenterol Hepatol; 2006 Mar; 29(3):122-4. PubMed ID: 16507278
    [No Abstract]   [Full Text] [Related]  

  • 62. HCV immune evasion and regulatory T cell activation: cause or consequence?
    Li H; Li T; Crispe IN; Tu Z
    Cell Mol Immunol; 2018 May; 15(5):536-538. PubMed ID: 29176743
    [No Abstract]   [Full Text] [Related]  

  • 63. Controversy on the role of FoxP3⁺ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections.
    Claassen MA; Janssen HL; de Knegt RJ; Boonstra A
    J Hepatol; 2014 Jan; 60(1):231-2. PubMed ID: 24045149
    [No Abstract]   [Full Text] [Related]  

  • 64. Reply to: "Controversy on the role of FoxP3⁺ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections".
    Langhans B; Spengler U
    J Hepatol; 2014 Jan; 60(1):232-4. PubMed ID: 24051070
    [No Abstract]   [Full Text] [Related]  

  • 65. Hepatitis C viral infection after orthotopic liver transplantation.
    Berenguer J; Prieto M; Mir J; Cordoba J; Rayón M
    Adv Exp Med Biol; 1994; 368():173-9. PubMed ID: 7741010
    [No Abstract]   [Full Text] [Related]  

  • 66. The evolution of occult Hepatitis C Virus after immunosuppression in advanced CKD patients.
    Martín-Gómez MA; Castillo-Aguilar I; Barril-Cuadrado G; Cabezas-Fernández T; Casado-Martín M; Cabello-Díaz M
    Nefrologia; 2015; 35(5):511-3. PubMed ID: 26306963
    [No Abstract]   [Full Text] [Related]  

  • 67. Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    Andréasson K; Waldenström J; Westin J; Norrgren H; Jönsson G; Nyström K; Lagging M
    J Hepatol; 2017 Sep; 67(3):649-651. PubMed ID: 28527663
    [No Abstract]   [Full Text] [Related]  

  • 68. Immunopathogenesis of Hepatitis C Virus Infection.
    Kaplan DE
    Gastroenterol Clin North Am; 2015 Dec; 44(4):735-60. PubMed ID: 26600217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Treatment of hepatitis C virus infection in children: Time for action.
    Indolfi G; D'Antiga L
    Liver Transpl; 2017 Apr; 23(4):427-429. PubMed ID: 28109055
    [No Abstract]   [Full Text] [Related]  

  • 70. Finding a role for Th17 cells in hepatitis C pathogenesis.
    Bowen DG
    J Gastroenterol Hepatol; 2012 Feb; 27(2):188-91. PubMed ID: 22260280
    [No Abstract]   [Full Text] [Related]  

  • 71. Platelets-to-lymphocyte ratio as a predictor of liver fibrosis and insulin resistance in hepatitis C virus infection: more evidence is needed.
    Huang R; Wang J; Xia J; Hao Y; Wu C
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):583. PubMed ID: 29579016
    [No Abstract]   [Full Text] [Related]  

  • 72. Is it Possible to Predict Advanced Fibrosis or Cirrhosis in Asian Patients With Hepatitis C?
    Ozalper V; Ozturker C; Ozturk E
    J Clin Gastroenterol; 2017 Jan; 51(1):87. PubMed ID: 27533111
    [No Abstract]   [Full Text] [Related]  

  • 73. Viral eradication and fibrosis resolution in post-liver transplant cholestatic hepatitis C virus.
    Mauro E; Crespo G; Montironi C; Londoño MC; Díaz A; Forns X; Navasa M
    Liver Transpl; 2018 May; 24(5):703-707. PubMed ID: 29385311
    [No Abstract]   [Full Text] [Related]  

  • 74. "Targeting" hepatitis C after liver transplantation.
    Londoño MC; Mariño Z; Forns X
    Liver Transpl; 2016 Jan; 22(1):9-11. PubMed ID: 26539895
    [No Abstract]   [Full Text] [Related]  

  • 75. "Who killed JR": Chronic hepatitis C or alcohol use disorders?
    Schwarzinger M; Rehm J; Mallet V
    J Hepatol; 2018 May; 68(5):1098-1099. PubMed ID: 29294316
    [No Abstract]   [Full Text] [Related]  

  • 76. The yin and yang of interleukin-2-mediated immunotherapy.
    Bluestone JA
    N Engl J Med; 2011 Dec; 365(22):2129-31. PubMed ID: 22129258
    [No Abstract]   [Full Text] [Related]  

  • 77. Hepatitis C Virus Relapse 78 Weeks After Completion of Successful Direct-Acting Therapy.
    Boschi C; Colson P; Tissot-Dupont H; Bernit E; Botta-Fridlund D; Aherfi S
    Clin Infect Dis; 2017 Sep; 65(6):1051-1053. PubMed ID: 28510632
    [No Abstract]   [Full Text] [Related]  

  • 78. Low-dose interleukin-2 and HCV-induced vasculitis.
    Oo YH; Mutimer D; Adams DH
    N Engl J Med; 2012 Apr; 366(14):1353-4; author reply 1354. PubMed ID: 22475612
    [No Abstract]   [Full Text] [Related]  

  • 79. What is the impact of treatment for hepatitis C virus infection?
    Wiktor SZ; Scott JD
    Lancet; 2017 Jul; 390(10090):107-109. PubMed ID: 28699578
    [No Abstract]   [Full Text] [Related]  

  • 80. Chronic hepatitis C after liver transplantation: a randomized study.
    Casanovas Taltavull T; Casais Alvarez LA
    Gastroenterology; 2004 Jan; 126(1):373-4. PubMed ID: 14753218
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.